Note 11 - Subsequent Events

12 Months Ended

Dec. 31, 2016

11.	Subsequent events

IPO and the concurrent private placement

March

14,

2017,

the Company completed its IPO on the NASDAQ Capital Market pursuant to which the Company issued

174,286

ordinary shares at

$20.00

per share for gross proceeds of

$3,486.

In conjunction with IPO, the Company issued

2,541,048

ordinary shares in a private placement to certain investors at

$20.00

per share for gross proceeds of

$50,821.

Immediately prior to the IPO, the Company issued

2,112,963

ordinary shares to Nereus Trust (Note

10)

and the relevant royalty payment arrangements with the seller of the patent of Plinabulin were terminated.

2017

Omnibus Incentive Plan.

In connection with the IPO, the Company’s board of directors and shareholders approved a new equity compensation plan, the

2017

Omnibus Incentive Plan, to provide an additional incentive to selected officers, employees, non-employee directors, independent contractors and consultants of the Company under certain conditions. Under the

2017

Omnibus Incentive Plan, the maximum number of the Company’s ordinary shares reserved for issuance is

2,137,037

shares.